William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors including the recent FDA approval of Sephience, which is expected to be a significant revenue driver for PTC Therapeutics. The approval came with a broad label for treating hyperphenylalaninemia in phenylketonuria (PKU) patients, which positions the company well in the market.
Furthermore, PTC Therapeutics has a strategic launch plan targeting key prescribers who account for the majority of PKU claims, and they are prioritizing patients who have not responded well to existing therapies. The company anticipates low barriers to access, with a supportive payer mix and strategies in place to navigate insurance requirements effectively. These factors collectively contribute to the positive outlook and the Buy rating for the stock.
Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Ultragenyx Pharmaceutical. According to TipRanks, Corwin has an average return of 5.7% and a 43.94% success rate on recommended stocks.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $78.00 price target.